Filtered By:
Specialty: Infectious Diseases
Countries: China Health
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1142 results found since Jan 2013.
Relationship between clinical symptom profiles and COVID-19 infection status during delta-dominant period versus omicron-dominant period – analysis of real-world data collected in Hiroshima Prefecture, Japan
COVID-19, caused by the severe acute respiratory syndrome coronavirus (SARS-CoV-2) spread rapidly around the world after December 2019, when the first case was diagnosed in Wuhan City, Hubei Province, China. As of 5 March 2023, over 759 million confirmed cases and over 6.8 million deaths have been reported globally [1]. In Japan, the first domestic case of COVID-19 transmission was reported on January 16, 2020 [2], and the pandemic has now entered its fourth year. Throughout this time, governments around the world have taken various preventative measures in response to the pandemic, from mask wearing and social distancing ...
Source: International Journal of Infectious Diseases - September 15, 2023 Category: Infectious Diseases Authors: Lola Mamazairovna Hujamberdieva, Odgerel Chimed-Ochir, Yui Yumiya, Junko Tanaka, Hiroki Ohge, Masao Kuwabara, Eisaku Kishita, Tatsuhiko Kubo Source Type: research
Arbidol: The current demand, strategies, and antiviral mechanisms
CONCLUSION: ARB is a broad-spectrum antiviral drug that inhibits several viruses in vivo and in vitro, with high safety profile and low resistance; the antiviral mechanisms of ARB deserve to be further explored and more high-quality clinical studies are required to establish the efficacy and safety of ARB.PMID:37647451 | DOI:10.1002/iid3.984
Source: Herpes - August 30, 2023 Category: Infectious Diseases Authors: Yue Kang Yin Shi Silu Xu Source Type: research
SARS-CoV-2 seroprevalence in pregnant women during the first three COVID-19 waves in The Gambia
SARS-CoV-2, the causative agent of the coronavirus disease 2019 (COVID-19), was first identified in December 2019 in Wuhan, China [1]. SARS-CoV-2 was rapidly transmitted globally, disrupting structures and systems; and causing millions of deaths. Globally, there were 278.7M COVID-19 cases and 5.39M attributable deaths by December 2021 [2], 21 months after the World Health Organization (WHO) declared COVID-19 a pandemic [3]. Nigeria reported the first case in Sub-Saharan Africa (SSA) on 28 January 2020 [4].
Source: International Journal of Infectious Diseases - August 14, 2023 Category: Infectious Diseases Authors: Ramatoulie E. Janha, Alasana Bah, Hawanatu Jah, Fatima Touray, Yahaya Idris, Saikou Keita, Yassin Gaye, Samba Jallow, Tisbeh Faye-Joof, Baboucarr Njie, Rachel Craik, Nuredin I. Mohammed, Peter von Dadelszen, Umberto D'Alessandro, Anna Roca, the PRECISE Ne Source Type: research
Vaccine-induced and hybrid immunity to SARS-CoV-2 after three or four doses of BNT162b2 - results from 22 months follow-up of a healthcare workers cohort, Israel, 2020-2022
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has killed at least seven million worldwide since its emergence in China in late 2019 [1] and became the most significant global health crisis since the 1918 influenza pandemic [2]. In order to mitigate the spread of the pandemic, non-pharmaceutical interventions such as protective equipment and social distancing as well as the rapid development and mass implementation COVID-19 vaccines, have been rolled out to prevent death, reduce the spread and severity of disease, and protect healthcare systems from becoming overwhelmed [2].
Source: International Journal of Infectious Diseases - August 10, 2023 Category: Infectious Diseases Authors: Michael Edelstein, Karine Wiegler Beiruti, Hila Ben-Amram, Netta Beer, Christian Sussan, Perachel Batya, Salman Zarka, Kamal Abu Jabal Source Type: research
Identification of active compounds of traditional chinese medicine derived from maxing shigan decoction for COVID-19 treatment: a meta-analysis and in silico study
CONCLUSION: This study demonstrates the important role of MXSGD-related TCM in the treatment of COVID-19.PMID:37481738 | DOI:10.1080/14787210.2023.2238899
Source: Expert Review of Anti-Infective Therapy - July 23, 2023 Category: Infectious Diseases Authors: Xiaodan Guo Yihua Lin Fengming He Ying Jin Simian Chen Ting Li Caisheng Wu Lin Zhang Xueqin Chen Source Type: research
Influence of COVID-19 pandemic on the virus spectrum in children with respiratory infection in Xuzhou, China: a long-term active surveillance study from 2015 to 2021
To investigate the impact of the coronavirus disease 2019 (COVID-19) outbreak on the prevalence of respiratory viruses among pediatric patients with acute respiratory infections in Xuzhou from 2015 –2021.
Source: BMC Infectious Diseases - July 13, 2023 Category: Infectious Diseases Authors: Rundong Cao, Yangguang Du, Jing Tong, Dong Xia, Qinqin Song, Zhiqiang Xia, Mi Liu, Haijun Du, Jun Han and Chen Gao Tags: Research Source Type: research
Safety, tolerability, pharmacokinetics, and immunogenicity of JMB2002 –an antibody against COVID-19: a phase 1 clinical trial in healthy Chinese adults
The emergence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and subsequent Coronavirus Disease 2019 (COVID-19) pandemic has resulted in a significant global public health burden, leading to a...
Source: BMC Infectious Diseases - June 27, 2023 Category: Infectious Diseases Authors: Guiling Chen, Ying Zhang, Kaiqi Wu, Tinghan Jin, Conggao Peng, Qi Jiang, Wenjuan Tian, Zhong Chen, Zhenwei Shen and Guoping Sheng Tags: Research Source Type: research
Cost-effectiveness of remdesivir for the treatment of hospitalized patients with COVID-19: a systematic review
ConclusionsBased on the results of the present study, remdesivir appears to be cost-effective in comparison with the standard of care in China, Turkey, and South Africa. Studies conducted in the United States show conflicting results, and combining remdesivir with baricitinib is cost-effective compared with remdesivir alone. However, the cost-effectiveness of remdesivir in low-income countries remains unknown. Thus, more studies in different countries are required to determine the cost-effectiveness of this drug.
Source: Infectious Diseases of Poverty - April 20, 2023 Category: Infectious Diseases Source Type: research
Mediating role of resilience in the relationship between COVID-19 related stigma and mental health among COVID-19 survivors: a cross-sectional study
ConclusionStigma has a significant negative impact on mental health, while resilience plays a mediator role in the relationship between stigma and mental health among COVID-19 survivors. Based on our study, we suggested that when designing psychological interventions for COVID-19 survivors, consideration should be taken into account to reduce stigma and improve resilience.
Source: Infectious Diseases of Poverty - March 28, 2023 Category: Infectious Diseases Source Type: research
Reduction in COVID-19 related resource loss and decline in prevalence of probable depression in Chinese adults: an application of the Conservation of Resource Theory
ConclusionsThe lessening of the resource losses might have fully accounted for the significant decline in probable depression from Month 3 to 15 since the first COVID-19 outbreak in Hong Kong, China. The level of depression might have increased during the first phase of the pandemic, but might decline in the later phases if resources losses could be lessened. All stakeholders should hence work together to minimize individuals ’ COVID-19-related resource losses to prevent depression in the general population, as COVID-19 might be lasting.
Source: Infectious Diseases of Poverty - March 16, 2023 Category: Infectious Diseases Source Type: research
Non-pharmaceutical interventions for COVID-19 reduced the incidence of infectious diseases: a controlled interrupted time-series study
ConclusionsNPIs for COVID-19 could effectively control the prevalence of infectious diseases, with patterns of risk varying by socioeconomic status. These findings have important implications for informing targeted strategies to prevent infectious diseases.
Source: Infectious Diseases of Poverty - March 9, 2023 Category: Infectious Diseases Source Type: research
Concomitant Severe Psoriasis and Bullous Pemphigoid Induced by COVID-19
Trop Med Infect Dis. 2023 Feb 8;8(2):107. doi: 10.3390/tropicalmed8020107.ABSTRACTCoronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first isolated in Wuhan, China, is currently a pandemic. At the beginning of the pandemic, pulmonary issues were the most discussed and studied. However, now 3 years later, the role of the dermatologist has become increasingly central. Often the diversity in the presentation of these manifestations has made it difficult for the dermatologist to recognize them. In addition to the common symptoms involving fever, cough, dyspnea, and hypo...
Source: Herpes - February 24, 2023 Category: Infectious Diseases Authors: Fabrizio Martora Teresa Battista Gabriella Fabbrocini Matteo Megna Source Type: research
